City begins $1.3 million Old Town construction project
The city is investing about $1.3 million to add a new roundabout to Mountain Road. 'Roundabouts are much safer than traditional intersections, and they keep traffic moving, so that keeps pollution down. In this case, it also will connect to the Rail Trail, which we're excited about,' shared Dan Mayfield, spokesperson for the City of Albuquerque.
New restaurant in Old Town takes over space left by beloved eatery
Research shows the tight circle of a roundabout forces drivers to slow down when entering and circulating, making it safer for pedestrians to cross. 'I think the roundabout will be a good idea from 14th down to Rio Grande. The speed limit is supposed to be 18, and very seldom are cars going that slow on this road,' shared Mitch Rolland, a resident of the Sawmill neighborhood.
The new roundabout will provide a widened crossing for users to cross from the Rail Trail, Tiguex Park, and to the Old Town area.
The city says this project is part of a series of infrastructure improvements to the area. 'We're improving the whole area there, and it's part of a major, major infrastructure improvement for the Sawmill neighborhood,' continued Mayfield.
The project is scheduled to run through October to be completed by the time of this year's Balloon Fiesta.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a minute ago
- Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma's oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. Cyclins (including cyclins A and B) are a family of proteins that function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs). Cancers driven by high E2F activity, such as small cell lung cancer (SCLC) and other tumors with RB1 alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. In preclinical models, cyclin A/B RxL inhibitors: Blocked the cyclin A-E2F interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently disrupted the cyclin B-Myt1 interaction, removing a critical safety brake and forcing damaged tumor cells through division, causing tumor cell death. Produced robust anti-tumor activity, including in chemotherapy-resistant SCLC patient-derived xenograft models. The publication, which was co-authored by scientists from Circle Pharma and the Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, can be accessed here (doi: 10.1038/s41586-025-09433-w). 'We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature,' said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. 'This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins. With our first-in-human Phase 1 study of CID-078 well underway, we are eager to see the innovative research outlined in this publication translate into new, high-impact therapeutic options for people living with cancer.' 'These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F-driven cancers, such as cancers with RB1 alterations, which includes nearly all SCLCs, up to half of triple-negative breast cancers, and subsets of other solid tumors,' said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. 'Circle Pharma's cell-permeable, oral macrocycles are designed to overcome the limitations of other therapeutic modalities and are ideally positioned to access cyclins and other historically undruggable targets, offering exciting potential for patients with cancer.' About CID-078, Circle Pharma's Oral Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations. About Circle Pharma Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company's lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at and follow us on LinkedIn and X.
Yahoo
an hour ago
- Yahoo
Evercore ISI Lowered the Firm's PT on Intuitive Surgical (ISRG), Kept an In Line Rating
Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On July 23, Evercore ISI lowered the firm's price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) from $550 to $535, while keeping an In Line Rating on the stock. The rating follows the company's fiscal second-quarter earnings call for 2025. The company exceeded both revenue and EPS expectations during the quarter, driven by improved system sales. Intuitive Surgical, Inc. (NASDAQ:ISRG) posted $2.44 billion in revenue, up 21.4% year-over-year and ahead of expectations by $87.21 million. The EPS of $2.19 also came in ahead of consensus by $0.27. A medical team performing minimally invasive surgery with a da Vinci Surgical System. Despite these impressive sales figures, the firm remains uncertain regarding the company's potential to sustain the momentum gained in the second quarter, thus maintaining a Hold rating on the stock. Intuitive Surgical, Inc. (NASDAQ:ISRG) develops and markets advanced robotic-assisted surgical systems, including the da Vinci surgical systems and the Ion endoluminal system. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Baird Keeps Buy Rating on Palo Alto Networks (PANW), Reiterates PT
Palo Alto Networks, Inc. (NASDAQ:PANW) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 14, Shrenik Kothari from Robert W. Baird maintained a Buy rating on Palo Alto Networks, Inc. (NASDAQ:PANW) with a price target of $230. The analyst noted that the company is heading into its fiscal fourth quarter with favorable conditions. Kothari expects the revenue and annual recurring revenue to grow significantly year-over-year due to easier comparison. Moreover, the company acquired CYBR, and the analyst believes that this strategically improves the company's platform. He also likes the current valuation of the company, making it an attractive risk/reward situation. A cutting-edge computer lab full of IT experts monitoring the security of multiple systems. Palo Alto Networks, Inc. (NASDAQ:PANW) provides AI-powered security solutions for networks, cloud environments, and security operations. While we acknowledge the potential of PANW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
